Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428690 | 0.76 | MAPT (0.59) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3870350 | 0.76 | LMNA (0.54) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14010913 | 0.66 | TGM2 (0.75) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16082480 | 0.66 | TP53 (0.81) | KMT2AMEN1ALDH1A1MAPTRXFP1 | |
| SCHEMBL16082491 | 0.66 | TP53 (0.85) | KMT2AMEN1MAPTLMNATP53 | |
| SCHEMBL3874256 | 0.65 | CYP2C9 (0.57) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10284846 | 0.64 | HDAC6 (0.46) | ALDH1A1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL6034185 | 0.64 | TGM2 (1.00) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15768048 | 0.64 | TGM2 (0.76) | ALDH1A1TGM2 | |
| SCHEMBL15766133 | 0.63 | KDR (0.59) | ALDH1A1SMN1; SMN2LMNATGM2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | KMT2A 3399/4885MEN1 3058/4885ALDH1A1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.